AnaptysBio, Inc. (NASDAQ:ANAB) shares reached a new 52-week high on Monday . The company traded as high as $30.69 and last traded at $30.67, with a volume of 44,213 shares trading hands. The stock had previously closed at $27.26.
A number of research firms recently weighed in on ANAB. Stifel Nicolaus raised their price objective on AnaptysBio from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 2nd. Zacks Investment Research lowered AnaptysBio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 25th. Finally, Robert W. Baird assumed coverage on AnaptysBio in a research report on Monday, July 10th. They set an “outperform” rating and a $36.00 price objective for the company. Six analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $33.67.
The firm’s market cap is $448.74 million. The company’s 50 day moving average is $24.30 and its 200 day moving average is $24.51.
In other AnaptysBio news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Holdings A/S Novo sold 491,294 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the completion of the sale, the insider now directly owns 2,952,527 shares in the company, valued at $62,357,370.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 777,640 shares of company stock worth $16,705,386.
Large investors have recently bought and sold shares of the company. Frazier Management LLC purchased a new stake in AnaptysBio during the first quarter valued at about $102,354,000. Perceptive Advisors LLC purchased a new stake in AnaptysBio during the first quarter valued at about $24,474,000. Hamilton Lane Advisors LLC purchased a new stake in AnaptysBio during the first quarter valued at about $11,213,000. Marshall Wace North America L.P. purchased a new stake in AnaptysBio during the first quarter valued at about $6,924,000. Finally, MARSHALL WACE ASIA Ltd purchased a new stake in AnaptysBio during the first quarter valued at about $6,924,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “AnaptysBio, Inc. (NASDAQ:ANAB) Hits New 52-Week High at $30.69” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/08/19/anaptysbio-inc-nasdaqanab-reaches-new-12-month-high-at-30-69-updated-updated-updated.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
What are top analysts saying about AnaptysBio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc. and related companies.